Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (vol 398, pg 1344, 2021)

被引：0
|
作者：
Felip, Enriqueta
Altorki, Nasser
Zhou, Caicun
Csoszi, Tibor
Vynnychenko, Ihor
Goloborodko, Oleksandr
Luft, Alexander
Akopov, Andrey
Martinez-Marti, Alex
Kenmotsu, Hirotsugu
Chen, Yuh-Min
Chella, Antonio
Sugawara, Shunichi
Voong, David
Wu, Fan
Yi, Jing
Deng, Yu
McCleland, Mark
Bennett, Elizabeth
Gitlitz, Barbara
Wakelee, Heather
机构：
来源：
LANCET | 2021年 / 398卷 / 10312期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1686 / 1686
页数：1
相关论文
共 50 条
  • [21] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [22] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (vol 41, pg 1830, 2023)
    Herbst
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3877 - 3877
  • [23] Adjuvant treatment of completely resected stage IB-IIIA non-small-cell lung cancer. A retrospective study with cisplatin or carboplatin and oral vinorelbin
    Engel-Riedel, W.
    Magnet, F.
    Alten, N.
    Ludwig, C.
    Bachinger, A.
    Stoelben, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 86
  • [24] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
    O'Brien, Mary
    Paz-Ares, Luis
    Marreaud, Sandrine
    Dafni, Urania
    Oselin, Kersti
    Havel, Libor
    Esteban, Emilio
    Isla, Dolores
    Martinez-Marti, Alex
    Faehling, Martin
    Tsuboi, Masahiro
    Lee, Jong-Seok
    Nakagawa, Kazuhiko
    Yang, Jing
    Samkari, Ayman
    Keller, Steven M.
    Mauer, Murielle
    Jha, Nitish
    Stahel, Rolf
    Besse, Benjamin
    Peters, Solange
    LANCET ONCOLOGY, 2022, 23 (10): : 1274 - 1286
  • [25] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    LANCET, 2017, 389 (10066): : 255 - 265
  • [26] Adjuvant treatment of completely resected stage IB-IIIA non-small-cell lung cancer. A retrospective study with cisplatin or carboplatin and oral vinorelbine.
    Magnet, Friederike Sophie
    Alten, Nina
    Bachinger, Andreas
    Engel-Riedel, Walburga
    Ludwig, Corinna
    Stoelben, Erich
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer
    Scagliotti, GV
    Fossati, R
    Torri, V
    Crinó, L
    Giaccone, G
    Silvano, G
    Martelli, M
    Clerici, M
    Cognetti, F
    Tonato, M
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19): : 1453 - 1461
  • [28] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (vol 389, pg 255, 2017)
    Rittmeyer, A.
    Barlesi, F.
    Waterkamp, D.
    LANCET, 2017, 389 (10068): : E2 - E2
  • [29] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried E. E.
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Orlov, Sergey V.
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4007 - +
  • [30] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (vol 389, pg 255, 2016)
    Rittmeyer, A.
    Barlesi, F.
    Waterkamp, D.
    LANCET, 2017, 389 (10077): : E5 - E5
12345